BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...Number of patients Timepoint measured Primary endpoint(s) March 26th Ablynx unit of Sanofi (NASDAQ:SNY; Euronext:SAN) Vobarilizumab...
...B cells. Interactions between CD40 and CD40L also promote B cell activity. B cell activity: Vobarilizumab...
...of clinical trial you’d have to do.” Finally, data from Ablynx’s anti-IL-6 receptor (CD126) mAb vobarilizumab...
BioCentury | Mar 30, 2018
Clinical News

Ablynx's CD126 nanobody misses in Phase II for lupus

...Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) said vobarilizumab (ALX-0061) missed the primary endpoint in the Phase II STEADY...
...severe, active seropositive SLE to receive placebo or one of four dose regimens of subcutaneous vobarilizumab...
...Severity Index (CLASI), safety and pharmacokinetics Status: Phase II data Milestone: NA Alicia Parker vobarilizumab (ALX-0061, sc alx-0061, subcutaneous alx-0061) Ablynx...
BioCentury | Mar 26, 2018
Clinical News

Ablynx’s CD126 nanobody misses in Phase II for lupus

...Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) said vobarilizumab (ALX-0061) missed the primary endpoint in the Phase II STEADY...
...severe, active seropositive SLE to receive placebo or one of four dose regimens of subcutaneous vobarilizumab...
...€0.02 to €43.98 in Brussels and up $0.58 to $54.66 on NASDAQ. Alicia Parker vobarilizumab (ALX-0061, sc alx-0061, subcutaneous alx-0061) Ablynx...
BioCentury | Feb 3, 2018
Strategy

Road to acquisition

...the commercialization of caplacizumab and fund late-stage trials for two other wholly owned clinical assets, vobarilizumab...
...linker to create a bivalent molecule that has greater potency than a single Nanobody. Ablynx’s vobarilizumab...
...CD126), is linked to a Nanobody targeting human serum albumin to extend the molecule’s half-life. Vobarilizumab...
BioCentury | Jan 13, 2018
Finance

Assessing Ablynx

...less aggressive about Ablynx’s valuation prospects, citing pipeline risk. Its two other clinical programs are vobarilizumab...
BioCentury | Jan 12, 2018
Company News

Ablynx rejects Novo's $2.8B acquisition proposal

...on Dec. 7, was for €26.75 per share. The CVR is tied to Ablynx's nanobodies vobarilizumab...
...ALX-0171. Buysiders are watching for data expected this half from a Phase II trial of vobarilizumab...
...CD126), to treat systemic lupus erythematosus (SLE). AbbVie Inc. (NYSE:ABBV) has an option to license vobarilizumab...
BioCentury | Jan 8, 2018
Company News

Ablynx rejects Novo's $2.8B acquisition proposal

...on Dec. 7, was for €26.75 per share. The CVR is tied to Ablynx's nanobodies vobarilizumab...
...ALX-0171. Buysiders are watching for data expected this half from a Phase II trial of vobarilizumab...
...CD126), to treat systemic lupus erythematosus (SLE). AbbVie Inc. (NYSE:ABBV) has an option to license vobarilizumab...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Euronext:ABLX; NASDAQ:ABLX) Caplacizumab Acquired thrombotic thrombocytopenic purpura (TTP) Submit BLA 2018 Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) Vobarilizumab...
...N.V., which is slated to report data this half from a Phase II trial of vobarilizumab...
...S. “Chasing Zai.” BioCentury (2017) Li, V. “Making of Mepsevii.” BioCentury (2017) Virginia Li, Staff Writer AR101 ARGX-113 epacadostat JCAR017 Kymriah luspatercept Opdivo ozanimod patisiran Praluent Soliris subcutaneous ALXN1210 vobarilizumab Yervoy Yescarta Ablynx...
BioCentury | Oct 24, 2016
Company News

Ablynx, AbbVie deal

...AbbVie declined to exercise its option to license vobarilizumab (ALX-0061) from Ablynx to treat rheumatoid arthritis...
...CD126) “did not meet AbbVie’s criteria for moving forward.” AbbVie had an option to license vobarilizumab...
BioCentury | Oct 20, 2016
Company News

AbbVie declines Ablynx option in RA

...vobarilizumab (ALX-0061) to treat rheumatoid arthritis. Ablynx said it is seeking a new partner for vobarilizumab...
...full development in RA." AbbVie paid $175 million up front in 2013 for options to vobarilizumab...
...Ablynx gained 12% on July 7 after it reported data comparing three dosing regimens of vobarilizumab...
Items per page:
1 - 10 of 17